Form 4: Rhythm Pharma CHRO Sells Shares After Option Exercise

Rhythm Pharmaceuticals' Chief Human Resources Officer, Pamela J. Cramer, sold 3,350 shares of common stock for $105 per share after exercising stock options at $27.35, pursuant to a pre-arranged trading plan.

Summary

• Pamela J. Cramer, Chief Human Resources Officer of Rhythm Pharmaceuticals, Inc. (RYTM), executed a transaction on November 20, 2025.
• She exercised stock options to acquire 3,350 shares of common stock at an exercise price of $27.35 per share.
• Concurrently, she sold 3,350 shares of common stock at a price of $105 per share.
• These transactions were conducted under a Rule 10b5-1 trading plan adopted on August 7, 2025.
• Following these transactions, her direct beneficial ownership of common stock decreased from 24,164 shares to 20,814 shares.
• Her beneficial ownership of stock options decreased by 3,350, leaving 11,725 options remaining.

Sentiment

Score: 6

Explanation: The transaction is a routine insider sale under a Rule 10b5-1 plan, indicating a pre-scheduled event rather than a reaction to new company developments. The significant gain realized by the officer from exercising options and selling shares at a much higher market price is a positive for the individual, reflecting the company's stock performance.

Positives

• The sale was executed at a significantly higher price ($105) than the option exercise price ($27.35), indicating a substantial gain for the insider.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, which suggests the sale was not based on immediate, non-public information.

Negatives

• An insider sale, even if pre-planned, reduces the officer's direct equity stake in the company, which could be interpreted as a slight reduction in alignment with shareholder interests, though this is common for compensation.

Future Outlook

NA

Industry Context

NA

Related Party Transactions

• The transaction involves an officer of Rhythm Pharmaceuticals, Inc. selling company stock, which is a common form of related party transaction in the context of executive compensation and equity ownership.

Stakeholder Impact

• Shareholders: The sale reduces the direct equity stake of a key executive, but the pre-planned nature mitigates concerns about immediate negative sentiment. It also demonstrates the liquidity and value of the company's stock for executives.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine, pre-planned insider transaction where an executive exercised stock options and sold shares. Such transactions are common for executive compensation and do not typically signal a change in the company's fundamental outlook or performance. The sale was executed under a Rule 10b5-1 plan, which suggests it was not based on new, non-public information. Therefore, this specific filing alone does not provide a basis for a "buy" or "sell" recommendation, and a "hold" stance is appropriate as investors should rely on broader company fundamentals and market conditions.

Keywords

Rhythm Pharmaceuticals, RYTM, Pamela J. Cramer, Insider Trading, Form 4, Stock Options, Share Sale, Rule 10b5-1, Chief Human Resources Officer, Equity Compensation